Cargando…
Arzneimittelinduzierte Lungenerkrankungen
It is well-known that more than 350 drugs can cause unwanted effects in the lungs, bronchi, and neighboring structures of the thorax with a corresponding spectrum of pathological changes. Cardinal symptoms are often new onset of dyspnea on exertion and a cough that is usually dry. Further diagnostic...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101552/ https://www.ncbi.nlm.nih.gov/pubmed/32288714 http://dx.doi.org/10.1007/s10405-007-0149-9 |
_version_ | 1783511649699758080 |
---|---|
author | Ukena, D. |
author_facet | Ukena, D. |
author_sort | Ukena, D. |
collection | PubMed |
description | It is well-known that more than 350 drugs can cause unwanted effects in the lungs, bronchi, and neighboring structures of the thorax with a corresponding spectrum of pathological changes. Cardinal symptoms are often new onset of dyspnea on exertion and a cough that is usually dry. Further diagnostic work-up includes comprehensive pulmonary function testing with determination of diffusing capacity, high-resolution computed tomography, and bronchoscopy with bronchoalveolar lavage. There is no specific pathological alteration for a defined drug. In case of doubt the potentially pneumotoxic drug should be discontinued. An attempt should be made to treat severely compromised lung function with systemic corticosteroids. |
format | Online Article Text |
id | pubmed-7101552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-71015522020-03-31 Arzneimittelinduzierte Lungenerkrankungen Ukena, D. Pneumologe (Berl) CME Weiterbildung • Zertifizierte Fortbildung It is well-known that more than 350 drugs can cause unwanted effects in the lungs, bronchi, and neighboring structures of the thorax with a corresponding spectrum of pathological changes. Cardinal symptoms are often new onset of dyspnea on exertion and a cough that is usually dry. Further diagnostic work-up includes comprehensive pulmonary function testing with determination of diffusing capacity, high-resolution computed tomography, and bronchoscopy with bronchoalveolar lavage. There is no specific pathological alteration for a defined drug. In case of doubt the potentially pneumotoxic drug should be discontinued. An attempt should be made to treat severely compromised lung function with systemic corticosteroids. Springer-Verlag 2007-04-26 2007 /pmc/articles/PMC7101552/ /pubmed/32288714 http://dx.doi.org/10.1007/s10405-007-0149-9 Text en © Springer Medizin Verlag 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | CME Weiterbildung • Zertifizierte Fortbildung Ukena, D. Arzneimittelinduzierte Lungenerkrankungen |
title | Arzneimittelinduzierte Lungenerkrankungen |
title_full | Arzneimittelinduzierte Lungenerkrankungen |
title_fullStr | Arzneimittelinduzierte Lungenerkrankungen |
title_full_unstemmed | Arzneimittelinduzierte Lungenerkrankungen |
title_short | Arzneimittelinduzierte Lungenerkrankungen |
title_sort | arzneimittelinduzierte lungenerkrankungen |
topic | CME Weiterbildung • Zertifizierte Fortbildung |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101552/ https://www.ncbi.nlm.nih.gov/pubmed/32288714 http://dx.doi.org/10.1007/s10405-007-0149-9 |
work_keys_str_mv | AT ukenad arzneimittelinduziertelungenerkrankungen |